Cargando…

A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia

PI3Kδ (idelalisib) and BTK (ibrutinib) inhibitors have demonstrated significant clinical activity in chronic lymphocytic leukemia (CLL) interfering with the cross-talk between CLL cells and the lymph node microenviroment, yet their mechanism of action remains to be fully elucidated. Here, we develop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Primo, Daniel, Scarfò, Lydia, Xochelli, Aliki, Mattsson, Mattias, Ranghetti, Pamela, Espinosa, Ana Belén, Robles, Alicia, Gorrochategui, Julian, Martínez-López, Joaquín, de la Serna, Javier, González, Marcos, Gil, Alberto Chaparro, Anguita, Eduardo, Iraheta, Sandra, Munugalavadla, Veerendra, Quéva, Christophe, Tannheimer, Stacey, Rosenquist, Richard, Stamatopoulos, Kostas, Ballesteros, Joan, Ghia, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995261/ https://www.ncbi.nlm.nih.gov/pubmed/29899839 http://dx.doi.org/10.18632/oncotarget.25419

Ejemplares similares

Assessing Patients’ Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece
por: Karamanidou, Christina, et al.
Publicado: (2021)

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
por: de Weerdt, Iris, et al.
Publicado: (2017)

Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
por: Maffei, Rossana, et al.
Publicado: (2015)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
por: Falchi, Lorenzo, et al.
Publicado: (2016)

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
por: Kreuzer, Karl-Anton, et al.
Publicado: (2019)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia
por: Montraveta, Arnau, et al.
Publicado: (2015)

Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion
por: Coelho, H., et al.
Publicado: (2017)

P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
por: Scarfò, Lydia, et al.
Publicado: (2023)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

Infrequent “chronic lymphocytic leukemia-specific” immunoglobulin stereotypes in aged individuals with or without low-count monoclonal B-cell lymphocytosis
por: Agathangelidis, Andreas, et al.
Publicado: (2021)

Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations
por: Agathangelidis, Andreas, et al.
Publicado: (2018)

High-throughput analysis of the T-cell receptor gene repertoire in low-count monoclonal B-cell lymphocytosis reveals a distinct profile from chronic lymphocytic leukemia
por: Agathangelidis, Andreas, et al.
Publicado: (2020)

T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations
por: Vlachonikola, Elisavet, et al.
Publicado: (2023)

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
por: Cuneo, Antonio, et al.
Publicado: (2018)

Crystal structure of idelalisib tert-butanol monosolvate dihydrate
por: Nerdinger, Sven, et al.
Publicado: (2019)

Integrating multiple immunogenetic data sources for feature extraction and mining somatic hypermutation patterns: the case of “towards analysis” in chronic lymphocytic leukaemia
por: Kavakiotis, Ioannis, et al.
Publicado: (2016)

Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses
por: Alflen, Astrid, et al.
Publicado: (2018)

Rapid and complete response to idelalisib in a case of Richter syndrome
por: Bagacean, Cristina, et al.
Publicado: (2019)

Idelalisib induces PUMA-dependent apoptosis in colon cancer cells
por: Yang, Shida, et al.
Publicado: (2016)

Idelalisib may have the potential to increase radiotherapy side effects
por: Gryc, Thomas, et al.
Publicado: (2017)

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
por: Kost, Sara E. F., et al.
Publicado: (2019)

A novel strategy for the manufacture of idelalisib: controlling the formation of an enantiomer
por: Mekala, Nagaraju, et al.
Publicado: (2018)

An unusual case of Idelalisib‐related pneumonitis with severe respiratory failure
por: Sousa, Domingos, et al.
Publicado: (2020)

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial
por: Ghia, Paolo, et al.
Publicado: (2020)

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo
por: Palazzo, Adam, et al.
Publicado: (2018)

PB2349: LESSONS LEARNED FROM THE MYPAL DIGITAL HEALTH INTERVENTION: CAPITALIZING ON THE PATIENT REPORTED OUTCOMES (PRO) PARADIGM TOWARDS A PARTICIPATORY HEALTHCARE FOR PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Karamanidou, C., et al.
Publicado: (2022)

P1489: HIGH DOSE IRON IMPAIRS MALIGNANT B-CELL VIABILITY AND IMPROVES IMMUNE ANTITUMOR FUNCTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Bordini, Jessica, et al.
Publicado: (2023)

Management of adverse events associated with idelalisib treatment: expert panel opinion
por: Coutré, Steven E., et al.
Publicado: (2015)

Idelalisib: Practical Tools for Identifying and Managing Adverse Events in Clinical Practice
por: Driscoll, Nancy
Publicado: (2016)

Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphoma
por: Hengeveld, Paul J, et al.
Publicado: (2020)

PB2362: BEST PRACTICES ON EMPOWERING AND INVOLVING PATIENTS LIVING WITH HEMATOLOGICAL MALIGNANCIES ON THE DEVELOPMENT OF NOVEL PATIENT-REPORTED OUTCOME MEASURES
por: Vrontaras, N., et al.
Publicado: (2022)

Toll-like receptor 9 stimulation can induce IκBζ expression and IgM secretion in chronic lymphocytic leukemia cells
por: Fonte, Eleonora, et al.
Publicado: (2017)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ
por: Somoza, John R., et al.
Publicado: (2015)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dntmlefsbu5135o5sudld0kg2j